Exicure Soars Following Promising Cell-Enhancing Outcomes in Blood Cancer Study
Stock Performance: Exicure, Inc. (NASDAQ: XCUR) saw a significant increase in stock price, rising 63.23% to $8.70, with a trading volume of 13.62 million shares compared to the average of 151.41 thousand.
Clinical Trial Results: The company reported positive results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients, with approximately 90% of participants achieving the primary endpoint.
Mechanism of Action: Burixafor is an investigational small molecule that enhances the mobilization of HPCs by blocking CXCL12 binding to CXCR4 receptors, allowing for rapid collection of CD34+ cells from the blood.
Safety and Efficacy: The combination treatment was well tolerated with no significant adverse events, and a high percentage of participants previously treated with daratumumab still achieved the primary endpoint, indicating its effectiveness even in challenging cases.
Get Free Real-Time Notifications for Any Stock
Analyst Views on XCUR
About XCUR
About the author
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
